GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clinuvel Pharmaceuticals Ltd (OTCPK:CLVLY) » Definitions » Receipts from Customers

CLVLY (Clinuvel Pharmaceuticals) Receipts from Customers : $56.02 Mil (TTM As of Jun. 2024)


View and export this data going back to 2004. Start your Free Trial

What is Clinuvel Pharmaceuticals Receipts from Customers?

Clinuvel Pharmaceuticals's Receipts from Customers for the six months ended in Jun. 2024 was $26.85 Mil.

Clinuvel Pharmaceuticals's Receipts from Customers for the trailing twelve months (TTM) ended in Jun. 2024 was $56.02 Mil.


Clinuvel Pharmaceuticals Receipts from Customers Historical Data

The historical data trend for Clinuvel Pharmaceuticals's Receipts from Customers can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clinuvel Pharmaceuticals Receipts from Customers Chart

Clinuvel Pharmaceuticals Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Receipts from Customers
Get a 7-Day Free Trial Premium Member Only Premium Member Only 20.21 29.61 46.66 50.25 55.79

Clinuvel Pharmaceuticals Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Receipts from Customers Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 24.94 24.38 26.00 29.17 26.85

Clinuvel Pharmaceuticals Receipts from Customers Calculation

A company's cash flow from operations for a time period can be determined using either the direct or indirect method. The indirect method modifies the operating section from accrual accounting to a cash basis by taking the net income generated in a period and adding or subtracting changes in the asset and liability accounts to determine the implied cash flow. However, the direct method uses actual cash inflows and outflows from the company's operations directly. Receipts from Customers represents payment received from customers in the direct cash flow method.

Receipts from Customers for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was $56.02 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Clinuvel Pharmaceuticals Receipts from Customers Related Terms

Thank you for viewing the detailed overview of Clinuvel Pharmaceuticals's Receipts from Customers provided by GuruFocus.com. Please click on the following links to see related term pages.


Clinuvel Pharmaceuticals Business Description

Address
535 Bourke Street, Level 22, Melbourne, VIC, AUS, 3000
Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.

Clinuvel Pharmaceuticals Headlines

From GuruFocus

First patient dosed in SCENESSE� DNA Repair Program

By Marketwired Marketwired 09-15-2020

Letter to shareholders from CLINUVEL's CEO

By GuruFocusNews GuruFocusNews 04-29-2022

CLINUVEL progresses vitiligo treatment program

By GuruFocusNews GuruFocusNews 05-10-2022

CLINUVEL progresses innovative DNA Repair Program

By Marketwired Marketwired 09-10-2020

FDA Approves SCENESSE® For Genetic Disorder

By Marketwired Marketwired 10-09-2019

CLINUVEL Drug Significantly Reduces Critical UV Skin Damage in Fair-Skinned Individuals

By Stock market mentor Stock market mentor 02-02-2023

CLINUVEL progresses vitiligo treatment program

By GuruFocusNews GuruFocusNews 05-20-2022